JP5651681B2 - 代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法 - Google Patents
代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法 Download PDFInfo
- Publication number
- JP5651681B2 JP5651681B2 JP2012503692A JP2012503692A JP5651681B2 JP 5651681 B2 JP5651681 B2 JP 5651681B2 JP 2012503692 A JP2012503692 A JP 2012503692A JP 2012503692 A JP2012503692 A JP 2012503692A JP 5651681 B2 JP5651681 B2 JP 5651681B2
- Authority
- JP
- Japan
- Prior art keywords
- another embodiment
- optionally substituted
- compound
- pyridin
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C(C[C@@]1C2)C1C1[C@]2*CC1 Chemical compound C(C[C@@]1C2)C1C1[C@]2*CC1 0.000 description 45
- RLHRNNPHMGHLOW-UHFFFAOYSA-N C(Cc1c(C2)[o]c(-c3ccccc3)n1)C2c1ccccn1 Chemical compound C(Cc1c(C2)[o]c(-c3ccccc3)n1)C2c1ccccn1 RLHRNNPHMGHLOW-UHFFFAOYSA-N 0.000 description 1
- PVDWFNKJWUXAQD-FMIVXFBMSA-N C/C(/c1nc(CN(CCC2)c3cc(C#N)cc([IH+])c3)c2[o]1)=C\N=C/N Chemical compound C/C(/c1nc(CN(CCC2)c3cc(C#N)cc([IH+])c3)c2[o]1)=C\N=C/N PVDWFNKJWUXAQD-FMIVXFBMSA-N 0.000 description 1
- QEECYYUMBXZDHP-VKNVFSQXSA-N C/C=C\C(\C(NC(CC(CC1)C(CC(C#N)=C2)C=C2F)C1O)=O)=N/C Chemical compound C/C=C\C(\C(NC(CC(CC1)C(CC(C#N)=C2)C=C2F)C1O)=O)=N/C QEECYYUMBXZDHP-VKNVFSQXSA-N 0.000 description 1
- YTPTYKPEJVXSSS-UHFFFAOYSA-N C1NC(c2nc(CN(CCC3)C4=NC=CCN4)c3[o]2)=CC=C1 Chemical compound C1NC(c2nc(CN(CCC3)C4=NC=CCN4)c3[o]2)=CC=C1 YTPTYKPEJVXSSS-UHFFFAOYSA-N 0.000 description 1
- KTSYYJWODWMCFU-UHFFFAOYSA-N C1[IH]CC1c1c(C(CCC2)Cc3c2[o]c(-c2ccccn2)n3)nccc1 Chemical compound C1[IH]CC1c1c(C(CCC2)Cc3c2[o]c(-c2ccccn2)n3)nccc1 KTSYYJWODWMCFU-UHFFFAOYSA-N 0.000 description 1
- LZZBOIMXTRAQBJ-UHFFFAOYSA-N C=C(CCC(C1)c(ccc(F)c2)c2Cl)C1Br Chemical compound C=C(CCC(C1)c(ccc(F)c2)c2Cl)C1Br LZZBOIMXTRAQBJ-UHFFFAOYSA-N 0.000 description 1
- VXQRCKIXUFFEES-UHFFFAOYSA-N C=C1C(C2=CC=CC[N-]2)=NC(C2)C1CCCN2c1cc(O)cc(Cl)c1 Chemical compound C=C1C(C2=CC=CC[N-]2)=NC(C2)C1CCCN2c1cc(O)cc(Cl)c1 VXQRCKIXUFFEES-UHFFFAOYSA-N 0.000 description 1
- LVFHXTSDKGRPEJ-UHFFFAOYSA-N C=C1N=CC=C1 Chemical compound C=C1N=CC=C1 LVFHXTSDKGRPEJ-UHFFFAOYSA-N 0.000 description 1
- LWLJLXWNZMGLJS-UHFFFAOYSA-N C=[Cl]c(c(F)ccc1)c1N(CC1)Cc2c1[o]c(-c1ccccn1)n2 Chemical compound C=[Cl]c(c(F)ccc1)c1N(CC1)Cc2c1[o]c(-c1ccccn1)n2 LWLJLXWNZMGLJS-UHFFFAOYSA-N 0.000 description 1
- WNCANHXQNWEVDT-UHFFFAOYSA-N CC(CC(O)=C1)C=C1N(CCC1)CC2=C1[U]C=N2 Chemical compound CC(CC(O)=C1)C=C1N(CCC1)CC2=C1[U]C=N2 WNCANHXQNWEVDT-UHFFFAOYSA-N 0.000 description 1
- PTPJMENZYKJWIB-UHFFFAOYSA-N CC(CCN(CC1C)S(c2ccc(C)cc2)(=O)=O)C1=O Chemical compound CC(CCN(CC1C)S(c2ccc(C)cc2)(=O)=O)C1=O PTPJMENZYKJWIB-UHFFFAOYSA-N 0.000 description 1
- IEUKKRQMRVLHEH-UHFFFAOYSA-N CC(CCNCC1)C1=O Chemical compound CC(CCNCC1)C1=O IEUKKRQMRVLHEH-UHFFFAOYSA-N 0.000 description 1
- CAYCNAIDYBTRJN-UHFFFAOYSA-N CC(SC1)=NC1c1nc(CN(CCC2)c3ccccn3)c2[o]1 Chemical compound CC(SC1)=NC1c1nc(CN(CCC2)c3ccccn3)c2[o]1 CAYCNAIDYBTRJN-UHFFFAOYSA-N 0.000 description 1
- XDPPNKYTJJQFLL-UHFFFAOYSA-N CC1=C(N(CC2)CC(O)=C2/[I]=C/c2ccccn2)[I]=CC=C1 Chemical compound CC1=C(N(CC2)CC(O)=C2/[I]=C/c2ccccn2)[I]=CC=C1 XDPPNKYTJJQFLL-UHFFFAOYSA-N 0.000 description 1
- NKDPKFBONYDSIL-UHFFFAOYSA-N CCC(C=CCC1C)=C1F Chemical compound CCC(C=CCC1C)=C1F NKDPKFBONYDSIL-UHFFFAOYSA-N 0.000 description 1
- DWFWTFAXXUXWIU-UHFFFAOYSA-N CCC(CC(CC1)c(ccc(F)c2)c2Cl)C1O Chemical compound CCC(CC(CC1)c(ccc(F)c2)c2Cl)C1O DWFWTFAXXUXWIU-UHFFFAOYSA-N 0.000 description 1
- KFRAOTWECYRLBQ-GMJYNOSHSA-N CCC/C(/C#N)=C\C(\N(CCN1C2)CC1=NC2/C(/N=C)=C/C)=C/C Chemical compound CCC/C(/C#N)=C\C(\N(CCN1C2)CC1=NC2/C(/N=C)=C/C)=C/C KFRAOTWECYRLBQ-GMJYNOSHSA-N 0.000 description 1
- WXILNAIZBQNDID-VUVCFOEZSA-N CCC/C(/Cl)=C\C(c1c[n](CCN(C2)C3=C[C@@H](C)C=CNC3)c2n1)=C Chemical compound CCC/C(/Cl)=C\C(c1c[n](CCN(C2)C3=C[C@@H](C)C=CNC3)c2n1)=C WXILNAIZBQNDID-VUVCFOEZSA-N 0.000 description 1
- MJYCGWWQQSQAAH-UHFFFAOYSA-N CCc(cc1CC)cc(F)c1F Chemical compound CCc(cc1CC)cc(F)c1F MJYCGWWQQSQAAH-UHFFFAOYSA-N 0.000 description 1
- AVRCTMZRINPLPA-UHFFFAOYSA-N CCc1cc(Br)cc(C)c1O Chemical compound CCc1cc(Br)cc(C)c1O AVRCTMZRINPLPA-UHFFFAOYSA-N 0.000 description 1
- VUSHDGBREYPFNG-UHFFFAOYSA-N CN(CCCC1C=N)CC1NC(c1ccccc1)=O Chemical compound CN(CCCC1C=N)CC1NC(c1ccccc1)=O VUSHDGBREYPFNG-UHFFFAOYSA-N 0.000 description 1
- KNURSADGBZGWTK-UHFFFAOYSA-N CN/C=N\C(c1nc(CN(CCC2)c3cc(F)ccc3)c2[o]1)=C Chemical compound CN/C=N\C(c1nc(CN(CCC2)c3cc(F)ccc3)c2[o]1)=C KNURSADGBZGWTK-UHFFFAOYSA-N 0.000 description 1
- VPYCOEDDDUSRLQ-UHFFFAOYSA-N CNc(c(C=C)cc(Br)c1)c1F Chemical compound CNc(c(C=C)cc(Br)c1)c1F VPYCOEDDDUSRLQ-UHFFFAOYSA-N 0.000 description 1
- BTQZKHUEUDPRST-UHFFFAOYSA-N Cc1cccc(F)c1 Chemical compound Cc1cccc(F)c1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 1
- UBKKNWJGYLSDSJ-UHFFFAOYSA-N Cc1ncccc1C#N Chemical compound Cc1ncccc1C#N UBKKNWJGYLSDSJ-UHFFFAOYSA-N 0.000 description 1
- DDDYFFXGAXCRIA-UHFFFAOYSA-N Clc(cc1)ccc1C1=CCCC(CCC(C2)c3ccccn3)=C2O1 Chemical compound Clc(cc1)ccc1C1=CCCC(CCC(C2)c3ccccn3)=C2O1 DDDYFFXGAXCRIA-UHFFFAOYSA-N 0.000 description 1
- FWMGITPTCBGAKU-UHFFFAOYSA-N Clc1c(C2Cc3nc(-c4ncccc4)n[n]3CC2)nccc1 Chemical compound Clc1c(C2Cc3nc(-c4ncccc4)n[n]3CC2)nccc1 FWMGITPTCBGAKU-UHFFFAOYSA-N 0.000 description 1
- NVVYPLASQSOBEH-UHFFFAOYSA-N Clc1cncc(N(CCC2)Cc3c2[o]cn3)c1 Chemical compound Clc1cncc(N(CCC2)Cc3c2[o]cn3)c1 NVVYPLASQSOBEH-UHFFFAOYSA-N 0.000 description 1
- MQKCTYOYJCBKKX-UHFFFAOYSA-N FC1=CC=C(C2=NC(CN(CCC3)c4cccc(Cl)c4)C3O2)NC1 Chemical compound FC1=CC=C(C2=NC(CN(CCC3)c4cccc(Cl)c4)C3O2)NC1 MQKCTYOYJCBKKX-UHFFFAOYSA-N 0.000 description 1
- QHFYVCFHLPKQEW-UHFFFAOYSA-N Fc(ccc(N1CC(C2)N=C(C3=CC=CCN3)[U]C2CCC1)c1)c1I Chemical compound Fc(ccc(N1CC(C2)N=C(C3=CC=CCN3)[U]C2CCC1)c1)c1I QHFYVCFHLPKQEW-UHFFFAOYSA-N 0.000 description 1
- VWRYFQJPUGYMAL-UHFFFAOYSA-N Fc1cc(C(CC2)Cc3c2[o]c(-c(nc2)ccc2F)n3)ccc1 Chemical compound Fc1cc(C(CC2)Cc3c2[o]c(-c(nc2)ccc2F)n3)ccc1 VWRYFQJPUGYMAL-UHFFFAOYSA-N 0.000 description 1
- BHJUTCLWZGRJLF-UHFFFAOYSA-N Fc1cc(C(CC2)Cc3c2[o]c(-c2ccccn2)n3)ccc1 Chemical compound Fc1cc(C(CC2)Cc3c2[o]c(-c2ccccn2)n3)ccc1 BHJUTCLWZGRJLF-UHFFFAOYSA-N 0.000 description 1
- BYYJSUOFEVHSBG-UHFFFAOYSA-N N#CC1=CC(N2Cc3nc(-c4ccccn4)c[n]3CC2)=CC(F)=CC1 Chemical compound N#CC1=CC(N2Cc3nc(-c4ccccn4)c[n]3CC2)=CC(F)=CC1 BYYJSUOFEVHSBG-UHFFFAOYSA-N 0.000 description 1
- XRBBICQSFQCPQE-UHFFFAOYSA-N N#Cc1c(C(CC2)Cc3c2[o]c(-c2ncccc2)n3)nccc1 Chemical compound N#Cc1c(C(CC2)Cc3c2[o]c(-c2ncccc2)n3)nccc1 XRBBICQSFQCPQE-UHFFFAOYSA-N 0.000 description 1
- RJRAOANLYXNVGM-UHFFFAOYSA-N N#Cc1cc(-c2nc(CCC(C3)c4ncccc4C#N)c3[o]2)ccc1 Chemical compound N#Cc1cc(-c2nc(CCC(C3)c4ncccc4C#N)c3[o]2)ccc1 RJRAOANLYXNVGM-UHFFFAOYSA-N 0.000 description 1
- DKIWDQGAMCZINX-UHFFFAOYSA-N N#Cc1cc(F)cc(N(CCC2)CC3=C2[U]C(C([N-]C2)=CC=C2F)=N3)c1 Chemical compound N#Cc1cc(F)cc(N(CCC2)CC3=C2[U]C(C([N-]C2)=CC=C2F)=N3)c1 DKIWDQGAMCZINX-UHFFFAOYSA-N 0.000 description 1
- UQWWJJJGRFVHKG-UHFFFAOYSA-N NC(CNCCC1)=C1[ClH][Tl] Chemical compound NC(CNCCC1)=C1[ClH][Tl] UQWWJJJGRFVHKG-UHFFFAOYSA-N 0.000 description 1
- YODXJOWUSBDWSF-UHFFFAOYSA-N Oc1cncc(N2CC(N=CC3)=C3CCC2)c1 Chemical compound Oc1cncc(N2CC(N=CC3)=C3CCC2)c1 YODXJOWUSBDWSF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16666109P | 2009-04-03 | 2009-04-03 | |
| US61/166,661 | 2009-04-03 | ||
| US25579009P | 2009-10-28 | 2009-10-28 | |
| US61/255,790 | 2009-10-28 | ||
| PCT/US2010/029575 WO2010114971A1 (en) | 2009-04-03 | 2010-04-01 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522793A JP2012522793A (ja) | 2012-09-27 |
| JP2012522793A5 JP2012522793A5 (cg-RX-API-DMAC7.html) | 2013-05-16 |
| JP5651681B2 true JP5651681B2 (ja) | 2015-01-14 |
Family
ID=42244504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503692A Expired - Fee Related JP5651681B2 (ja) | 2009-04-03 | 2010-04-01 | 代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120029190A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2414340A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5651681B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2756989A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010114971A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010332819B2 (en) | 2009-12-18 | 2014-02-27 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors |
| EP2513117B1 (en) | 2009-12-18 | 2013-08-28 | Janssen Pharmaceutica, N.V. | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
| USRE48301E1 (en) | 2010-07-09 | 2020-11-10 | Abbvie B.V. | Fused heterocyclic derivatives as S1P modulators |
| US9090632B2 (en) | 2010-08-31 | 2015-07-28 | Vanderbilt University | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors |
| US8703946B2 (en) | 2010-12-08 | 2014-04-22 | Vanderbilt University | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors |
| EP2651222A4 (en) * | 2010-12-17 | 2014-04-30 | Univ Vanderbilt | BICYCLIC TRIAZOL AND PYRAZOLLACTAME AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| CN103874702B (zh) * | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| DK2799431T3 (en) | 2011-12-28 | 2018-03-26 | Fujifilm Corp | Hitherto unknown nicotinamide derivatives or salts thereof |
| BR112014031896A2 (pt) * | 2012-06-20 | 2017-06-27 | Univ Vanderbilt | composto, composição farmacêutica, e, método para o tratamento de um distúrbio |
| AR091225A1 (es) | 2012-06-22 | 2015-01-21 | Du Pont | Compuestos heterociclicos funguicidas |
| JP2016011257A (ja) * | 2012-10-23 | 2016-01-21 | 大日本住友製薬株式会社 | テトラヒドロオキサゾロピリジン誘導体 |
| WO2014096212A1 (en) | 2012-12-20 | 2014-06-26 | Janssen Pharmaceutica Nv | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS |
| KR102171710B1 (ko) | 2013-01-17 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체 |
| GB201321749D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| BR112017014226A2 (pt) * | 2014-12-29 | 2018-03-06 | Recordati Ireland Limited | derivados de heterociclilalquina e sua utilização como moduladores de receptores mglur5 |
| WO2016171181A1 (ja) * | 2015-04-21 | 2016-10-27 | 大日本住友製薬株式会社 | 2位置換縮合ピラゾール誘導体 |
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ip有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| JP2020504711A (ja) | 2016-12-21 | 2020-02-13 | バイオセリックス, インコーポレイテッド | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
| TWI754019B (zh) | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| EP3619208B1 (en) | 2017-05-01 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Crystalline forms of a jak inhibitor compound |
| AU2018261588A1 (en) | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| EA202091113A1 (ru) | 2017-11-02 | 2020-08-28 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv) |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| BR112021004087A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
| BR112021004063A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas heterocíclicas com 5 a 7 membros como inibidores de jak |
| EP3853229A1 (en) | 2018-10-29 | 2021-07-28 | Theravance Biopharma R&D IP, LLC | 2-azabicyclo hexane compound as jak inhibitor |
| KR20220149585A (ko) | 2020-03-02 | 2022-11-08 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제 화합물의 결정성 수화물 |
| KR102873922B1 (ko) * | 2020-07-03 | 2025-10-20 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리 화합물 및 이의 용도 |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| WO2023107722A1 (en) * | 2021-12-10 | 2023-06-15 | Prothena Biosciences Limited | Compounds for use in treating neurological disorders |
| EP4596554A4 (en) * | 2022-09-29 | 2025-12-10 | Suzhou Arkbiopharmaceutical Co Ltd | Fused AZA Cyclic Compound, its Preparation Process and its Use in Medicine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) * | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3503990A (en) * | 1967-01-31 | 1970-03-31 | Endo Lab | 6-aryl-4,5,6,7-tetrahydro-4-oxoindole derivatives |
| US3621027A (en) * | 1968-03-18 | 1971-11-16 | Endo Lab | 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales |
| WO2004101558A1 (en) * | 2003-05-13 | 2004-11-25 | F. Hoffmann-La Roche Ag | 2-imidazo-benzothiazoles as adenosine receptor ligands |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| SG149900A1 (en) * | 2004-02-18 | 2009-02-27 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| TW200800204A (en) * | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Bicyclic piperazines as metabotropic glutatmate receptor antagonists |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| EA201001205A1 (ru) * | 2008-01-24 | 2011-04-29 | Юсб Фарма, С.А. | Соединения, содержащие циклобутоксигруппу |
-
2010
- 2010-04-01 CA CA2756989A patent/CA2756989A1/en not_active Abandoned
- 2010-04-01 US US13/262,608 patent/US20120029190A1/en not_active Abandoned
- 2010-04-01 EP EP10712266A patent/EP2414340A1/en not_active Withdrawn
- 2010-04-01 WO PCT/US2010/029575 patent/WO2010114971A1/en not_active Ceased
- 2010-04-01 JP JP2012503692A patent/JP5651681B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010114971A1 (en) | 2010-10-07 |
| US20120029190A1 (en) | 2012-02-02 |
| EP2414340A1 (en) | 2012-02-08 |
| CA2756989A1 (en) | 2010-10-07 |
| JP2012522793A (ja) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522793A (ja) | 代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法 | |
| CA2904618C (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| KR20210124296A (ko) | 면역조절제, 조성물 및 이의 방법 | |
| JP6936224B2 (ja) | オクタヒドロピロロ[3,4−c]ピロール誘導体およびその使用 | |
| KR20110132564A (ko) | 히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법 | |
| JP2021533093A (ja) | モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物 | |
| KR102531689B1 (ko) | 6,7―디히드로피라졸로[1,5―α]피라진―4(5H)―온 화합물 및 MGLUR2 수용체의 음성 알로스테릭 조절제로서의 그 용도 | |
| CN107141309A (zh) | 杂芳基化合物及其使用方法 | |
| CN104725359A (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| WO2015088564A1 (en) | P2x4 receptor modulating compounds | |
| EP3148542A1 (en) | Factor xia inhibitors | |
| WO2016015593A1 (en) | FACTOR XIa INHIBITORS | |
| JP2019513792A (ja) | テトラヒドロイソキノリン誘導体 | |
| JP2020503293A (ja) | β−セクレターゼ阻害剤としてのオキサジン誘導体および使用方法 | |
| WO2017051276A1 (en) | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides | |
| JP5465716B2 (ja) | Nk1受容体アンタゴニストとしての5−[5−[2−(3,5−ビス(トリフルオロメチル)フェニル)−2−メチルプロパノイルメチルアミノ]−4−(4−フルオロ−2−メチルフェニル)]−2−ピリジニル−2−アルキル−プロリンアミド | |
| WO2018079759A1 (ja) | TrkA阻害活性を有する縮合複素環および縮合炭素環誘導体 | |
| CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| CN102666551A (zh) | 作为mglur5受体的变构调节剂的双环噻唑 | |
| ES2782088T3 (es) | Compuestos novedosos | |
| CN107759620B (zh) | 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途 | |
| KR20220079921A (ko) | M4 작용제로서의 2-아자스피로[3.4]옥탄 유도체 | |
| WO2012061019A2 (en) | Tricyclic mglur5 receptor modulators | |
| WO2023177700A2 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| TW201022233A (en) | (Pyrrolidin-2-yl)phenyl derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130326 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140707 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141028 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141117 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5651681 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |